Navigation Links
Avammune Therapeutics Announces Series A Funding and Formation of Scientific Advisory Board
Date:7/9/2019

Avammune Therapeutics Inc., (formerly known as Straximm Therapeutics), a spin-off from Aten Porus Lifesciences (Bangalore, India), today announced the raise of its Series A funding. The undisclosed Series A investment was raised through a consortium of private investors. Avammune also announced the appointment of its scientific advisory board comprised of:

Prof. George Church is Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world's only open-access information on human Genomic, Environmental & Trait data (GET). His innovations have contributed to nearly all "next generation" DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab's work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics (Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics) & synthetic biology / therapeutics (Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive). He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has co-authored 514 papers, 143 patent publications & one book (Regenesis).

Prof. Kate Fitzgerald is the Professor of Medicine, Director of the Program in Innate Immunity and The Worcester Foundation Chair in Biomedical Sciences at the University of Massachusetts (Amherst) Medical School. Prof. Fitzgerald received her Ph.D. in 1999 from Trinity College Dublin, Ireland, and later a post-doctoral fellow in the Department of Biochemistry working with Luke O’Neill (1999-2002). She joined the Division of Infectious Disease at the UMass Medical School as a Wellcome Trust Fellow in 2002 and joined the faculty in 2004. Her lab is focused on understanding the molecular mechanisms controlling the inflammatory response and employs multifaceted approaches including immunology, biochemistry, molecular biology and genetics to understand these mechanisms in both health and disease.

Prof. Jean-François Paquin studied chemistry at the Université Laval where he graduated with a BSc degree. In 2004, he received his PhD degree under the supervision of Professor Mark Lautens at the University of Toronto (Canada). After a postdoctoral stay in Professor Erick M. Carreira’s lab at the ETH Zürich (Switzerland), he was appointed assistant professor in 2005 at the Université Laval in Quebec City (Canada) as a Tier 2 Canada Research Chair in Organic and Medicinal Chemistry (2005–2010). In 2010, he was promoted to associate professor and his Canada Research Chair in Organic and Medicinal Chemistry was renewed (2010–2015). In June 2014, he was promoted to full professor. His current research interests include organofluorine chemistry, organic synthesis, catalysis, and medicinal chemistry. He has co-authored > 80 papers and received many prizes including the Keith Fagnou Award from the Canadian Society for Chemistry and a Research Fellowship from the Alexander von Humboldt Foundation.

“The rebranding of our company to Avammune emphasises our focus on harnessing the immune system to fight cancer and infectious diseases. This financing is the beginning of our Series A investment and we shall continue to raise additional funding for the round to drive further development of our programs,” said Arun B Papaiah, MBA, Founder and Chief Executive Officer of Avammune Therapeutics Inc.

“We are delighted to welcome George, Kate, and Jean-François on board who bring in unique sets of experience and expertise to Avammune. George being a pioneer in the area of genomics and precision medicine will be an asset as we continue to build our platform and grow our company. Similarly, Kate and Jean-François’ expertise in their respective fields of innate immunity and medicinal chemistry will help guide our R&D decision making process,” said Aditya Kulkarni, Ph.D., Founder and Chief Scientific Officer, Avammune Therapeutics Inc.

“The STING pathway has gained tremendous attention in recent years for its ability to not just attack cancer on its own but also improve the efficacy of other immuno-oncology therapeutics such as checkpoint inhibitors. This financing allows us to advance our proprietary STING modulator platform through preclinical development enabling us to expand our pipeline of treatments,” said Srinivasan Namala, Founder and Director, Avammune Therapeutics Inc.

Avammune shall be presenting results of its lead asset at the Immuno-Oncology Summit 2019 in Boston.

About Avammune Therapeutics Inc.
Avammune Therapeutics Inc., is a drug discovery company focused on the development of systemically administered small molecule modulators of the STING pathway to harness the immune system for fighting cancer. Additional information can be found at http://www.avammune.com

Media Inquiries
bd(at)avammune(dot)com

Read the full story at https://www.prweb.com/releases/avammune_therapeutics_announces_series_a_funding_and_formation_of_scientific_advisory_board/prweb16414835.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Better Therapeutics to Present Health Economic Data at ISPOR 2019
2. Actuate Therapeutics Completes $21.7 Million Series B Financing
3. Stealth BioTherapeutics Releases Promising Results from TAZPOWER Open-Label Extension Study in Barth Syndrome
4. VGXI Celebrates Grand Opening of New Flex-Scale Production Plant for GMP RNA and DNA Therapeutics Manufacturing
5. Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome
6. AccuGenomics Provides an AccuKit to Qura Therapeutics as Part of a Research Collaboration Agreement
7. CerSci Therapeutics Awarded Phase II SBIR Grant from the National Institute on Drug Abuse of the National Institutes of Health
8. United Therapeutics Corporation to Report Second Quarter 2017 Financial Results Before The Market Opens on Thursday, July 27, 2017
9. Prime Therapeutics Urges Caution on Mandates of Abuse-Deterrent Formulations of Opioids Citing Value Concerns
10. Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
11. Prostate Cancer Therapeutics Market ; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2019)... ... 19, 2019 , ... As the healthcare environment evolves, the ... pathologists, laboratory professionals and residents on the forefront of the profession, as well ... , Renowned Speakers Covering Crucial Topics , On September 11, Her Royal Highness ...
(Date:7/19/2019)... ... July 19, 2019 , ... Robinson Pharma, Inc., is proud to announce ... was audited by the Safe Quality Food (SQF) Institute using an accredited certification process ... Code for Manufacturing, Edition 8. , The SQF Certification program is trusted by buyers ...
(Date:7/18/2019)... ... July 18, 2019 , ... NeoTract, a wholly owned subsidiary ... urology, today announced that Timothy Lesser, MD, Skyline Urology in Torrance, CA has ... Lesser has achieved a high level of training and experience with the UroLift® ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... July 17, 2019 , ... In order to achieve the mission, the ... could occur, from the accident scene, to the moment the teeth are replanted and ... for treatment. , They identified seven points, so called links in a chain, along ...
(Date:7/17/2019)... ... July 17, 2019 , ... Dynamic Healthcare Systems, ... Advantage, Medicaid, and Marketplace programs is pleased to announce the introduction of an ... (EHR) integration at the point of care to providers and provider groups ...
(Date:7/17/2019)... ... ... It took just several small incisions by St. Luke's University Health Network ... under Amber Walck’s scalp, and suddenly her two-year agony with migraines was history. ... began without warning. About 39 million Americans suffer from migraines that range from ...
(Date:7/17/2019)... ... July 17, 2019 , ... Athena ... for human services providers worldwide, has been awarded a California Multiple Award Schedules ... procurement process for state and local government agencies in California by designating pre-approved ...
(Date:7/17/2019)... ... ... People considering surrogacy usually have an altruistic desire to help others who ... addition to creating a family, they have the opportunity to develop a very deep ... electing to have a child through the surrogacy process. An interview with an Intended ...
Breaking Medicine News(10 mins):